Eli Lilly and Boehringer Ingelheim's Jardiance and AstraZeneca's Forxiga have not been recommended for NHS use as a treatment for symptomatic chronic heart failure (CHF) w
UK cost-effectiveness agency NICE has said that guided, self-help digital cognitive behavioural therapy (CBT) apps can be used by the NHS for initial treatment of children
Alnylam's gene-silencing drug Amvuttra has been recommended as a treatment for hereditary transthyretin-related (ATTR) amyloidosis by NICE, paving the way for the drug to be made available
Cholesterol-lowering statin drugs could be available to millions more patients in the UK, if new recommendations from health technology assessment (HTA) organisation NICE are implemented.
One of the most highly-anticipated developments in pharma next year will be the FDA's verdict on Eisai's accelerated application for lecanemab in Alzheimer's disease, due early in January.<
